From LP Seats to Direct Bets: Animal Protein's Venture Pendulum

Anterra Capital and Elanco both moved in June, on opposite sides of the same strategic question.

Anterra reached a $100 million first close on its third specialist fund, against a $200 million target, raising institutional capital for the kind of food and agriculture companies most corporates cannot source on their own. Days later, Elanco said it would stand up Elanco Ventures, a $25 million multi-year corporate venture platform launching late in 2026.

The two firms are linked by a capital model.

For more than a decade, animal health and food corporates often bought exposure to startup markets indirectly, by committing capital as limited partners in specialist funds. Some still do. Elanco itself was a disclosed LP in Cultivian Sandbox Fund III in 2019. What the June announcements show is a sector working through which innovation categories matter enough to justify a closer, more direct seat.

The question has shifted. It used to be how a strategic gets any exposure to startups. It is now which categories warrant direct control.

Animal protein corporates have tested most available models. They have committed as LPs to specialist funds, built branded CVC arms, made selective balance-sheet investments, partnered with venture studios, sponsored accelerators, and acquired companies after outside investors absorbed the early risk.

The record reads as repeated experimentation rather than a clean migration from one model to the next.

That matters for how the public record is read. Direct CVC deals get press releases. LP commitments usually do not. Cultivian Sandbox Fund III is visible only because its manager chose to name strategic backers, a roster that included Elanco alongside ADM, Smithfield, Corteva, Ecolab, Koch and Sumitomo Chemical. Most LP positions never surface at all.

So the visible deal flow tends to overstate direct CVC and understate the quieter role of strategic LP capital. For a strategic, the model it picks reveals how much internal venture capability it has, and how specific its innovation needs have become.

An LP position is a way to rent pattern recognition.

A corporate that commits to a specialist fund gains deal flow, exposure to categories outside its own R&D, market intelligence, co-investment rights, and relationships with founders and other strategics, all without building a venture team. Zoetis is a returning LP in Anterra's new fund, sitting alongside Rabobank and Novo Holdings. That is a market leader buying a wide field of view rather than a position in any single company.

The limitation is control. An LP does not shape portfolio construction, cannot move at business-unit speed, and gains only a loose link between a fund's insight and its own commercial priorities. Several strategic LPs in one fund can also want different things from the same companies.

Anterra shows why the specialist model still earns its place. The firm incubated Invetx, a veterinary monoclonal antibody company, in 2018; Dechra acquired it in 2024 for up to $520 million. That is technical judgment and company-building most corporates cannot replicate internally.

The LP model works when a corporate wants breadth. It runs short when the corporate has a specific gap it wants to close with speed and ownership.

Elanco Ventures should be read for what its size signals.

At $25 million spread over several years, it is roughly one-sixth the size of Tyson's 2016 fund and a small figure against Elanco's revenue base. It looks like a strategic option-building tool rather than a financial vehicle, assuming the reported commitment holds. Its focus on pre-seed through Series A companies in therapeutics, supportive technologies and One Health, governed inside Elanco's Center of Strategic Growth under venture veteran Eric Steager, points the same way.

Chief executive Jeff Simmons framed the goal as visibility into emerging technologies rather than financial return. The likely targets, pet therapeutics, biologics, diagnostics, digital health and livestock sustainability, track Elanco's pipeline gaps after the Bayer Animal Health and KindredBio acquisitions.

This is a layer added to the stack. Elanco remains a Cultivian LP and a founding partner in the OneHealth Studio venture studio. The direct arm gives it earlier sight of companies its business units care about.

Merck Animal Health offers the contrast. Its venture arm, founded in 2017, was described as an extension of business development, and at least one portfolio company, cattle-sensor firm Quantified Ag, became an acquisition. Merck then built data and identification platforms through much larger deals, including Antelliq at $2.4 billion and Elanco's aquaculture business at $1.3 billion. If its venture pace looks slower now, it is more accurately called publicly quieter than inactive.

Direct CVC buys a closer look. It also demands business-unit pull. A venture arm without it becomes a collection of interesting holdings with little strategic consequence.

Animal health and protein processing use venture for different reasons, and should be judged against different mandates.

Animal health behaves like pharma. It needs pipeline replenishment, regulatory validation, intellectual property and de-risked assets it can license or acquire. Its CVC tends to scout platforms and adjacencies that feed an eventual deal.

Processors face lower margins and a different problem set: labor, yield, automation, food safety, supply chain resilience, emissions, and periodic pressure to hedge against alternative protein.

Tyson is the processor case. Tyson Ventures launched in December 2016 with $150 million, took an early Beyond Meat stake, and exited it before the 2019 IPO. As alternative protein valuations reset, the fund rotated toward automation, food safety and sustainability, backing companies such as livestock-carbon platform Athian. The vehicle persisted; the theme changed. A quieter Tyson reflects a changed capital allocation environment, not a failed model.

Animal health CVC reads as pipeline and platform scouting. Processor CVC reads as an operating hedge and a productivity search. Different mandates deserve different scorecards.

The next chapter of animal protein venture is likely to be more selective than the 2020 to 2021 peak, when agrifoodtech funding hit a record $51.7 billion before falling by roughly two-thirds.

Strategics now appear less willing to fund broad innovation stories and more willing to concentrate where business-unit pull is clear: poultry automation, animal disease detection, livestock monitoring, methane reduction, biologics and vaccines, feed efficiency, food safety diagnostics, aquaculture health, traceability, and data platforms that create switching costs.

For founders, strategic capital helps only when the corporate has a concrete reason to care. For funds, differentiated access and judgment remain the price of relevance. For corporates, the choice among LP, CVC, partnership and acquisition signals how much strategic confidence they have in a category. For investors, the visible round is a fraction of the picture; the quiet LP commitment, the pilot, the board observer seat and the eventual acquisition can matter as much.

Animal protein's venture market is not returning to the last cycle. It appears to be becoming more specific. That may make the next wave smaller, and strategically more revealing.